This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
UPTRAVI® (selexipag)
Medical Information
Transitioning To UPTRAVI From Inhaled Prostacyclin Therapy
Last Updated: 07/30/2025
SUMMARY
A summary of this response is provided as an interactive PDF (iPDF) that can be accessed by clicking the following link:
- UPTRAVI®
(selexipag) – Transitioning to UPTRAVI From Inhaled Prostacyclin Therapy - Minimum requirement to access interactive content: Adobe Acrobat Reader
- The executive summary infographic of the iPDF content is provided below
